What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

The move is the latest recruiting win for RBC Wealth Management as it continues to lure top talent away from big banks and ...

Boss also lowered his FY gross margin to 58.8%, representing a 70-basis point decline year-over-year, attributed to headwinds ...

As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...

J.P. Morgan analyst Ranjan Sharma maintained a Buy rating on Grab (GRAB – Research Report) on January 21 and set a price target of $5.60. The ...

This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of ...

Jamie Dimon, chairman and CEO, noted in the release that in the asset and wealth management division client net inflows ...

Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...

Plus: A stomach flu vaccine, the health impacts of California’s wildfires, lots of nine-figure deals for healthcare startups ...

J.P. Morgan Healthcare Conference is officially underway, bringing the healthcare and biopharma industries' biggest wheelers ...

LegalZoom.com (NASDAQ:LZ) was rising after J.P. Morgan upgraded the online platform on a positive inflection point in overall ...

J.P. Morgan analyst Mark Strouse maintained a Hold rating on Bloom Energy (BE – Research Report) yesterday and set a price target of $16.00.